Latest publications

Systemic treatment in atopic dermatitis after 2018: from experienced-based treatment to evidence-based treatment? De Bruin-Weller M et al. Br. J. Dermatol. 2020 Jun 21

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, De Bruin-Weller M et al. Am J Clin Dermatol 2020 Jun 17

Collodion babies: a 15-year retrospective multicenter study in the Netherlands. Evaluation of severity scores to predict the underlying disease. Cuperus E, Bolling MC, De Graaf M, Van den Akker PC, Van Gijn ME, Simon MEH et al. J. Am. Acad. Dermatol. 2020 Jun 11

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, Van der Schaft J et al. J. Allergy Clin. Immunol. 2020 Jun 08

European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Thyssen JP, Vestergaard C, Deleuran M, De Bruin-Weller MS, Bieber T, Taieb A et al. J Eur Acad Dermatol Venereol 2020 Jun 09:e16716

Dupilumab reduces absenteeism in patients with moderate-to-severe atopic dermatitis: pooled results from the LIBERTY AD SOLO clinical trials. De Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C et al. J. Am. Acad. Dermatol. 2020 Jun 03

Predictors of Food Sensitization in Children and Adults Across Europe. Lyons SA, Knulst AC, Burney PGJ, Fernández-Rivas M, Ballmer-Weber BK, Barreales L et al. J Allergy Clin Immunol Pract 2020 Apr 26

Prevalence of Food Sensitization and Food Allergy in Children across Europe. Lyons SA, Clausen M, Knulst AC, Ballmer-Weber BK, Fernandez-Rivas M, Barreales L et al. J Allergy Clin Immunol Pract 2020 Apr 21

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Spekhorst LS, Ariëns LFM, Van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ et al. Allergy 2020 Apr 17

Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. Spierings J, Sloeserwij A, Vianen ME, De Boer JH, Sigurdsson V, Van de Wijgert JHHM et al. Clin. Immunol. 2020 May; 214:108392

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T et al. J Eur Acad Dermatol Venereol 2020 Jun; 34(6):e241-e242

Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. Paller AS, Guttman-Yassky E, Irvine AD, Baselga E, De Bruin-Weller M, Jayawardena S et al. BMJ Open 2020 Mar 24; 10(3):e033507

Prevalence and Predictors of Uncontrolled Asthma in Children Referred for Asthma and Other Atopic Diseases. Kansen HM, Le TM, Uiterwaal C, Van Ewijk BE, Balemans W, Gorissen D et al. J Asthma Allergy 2020; 13:67-75

Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms. Versluis A, Knulst AC, Van Erp FC, Blankestijn MA, Meijer Y, Le TM et al. Clin. Exp. Allergy 2020 Apr; 50(4):479-486

Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. Alizadeh Aghdam M, Knol EF, Van den Elzen M, Den Hartog Jager C, Van Os-Medendorp H, Knulst AC et al. Clin. Exp. Allergy 2020 Mar; 50(3):364-371